Biome Australia (BIO) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
27 Jul, 2026Mission and values
Aims to prevent disease, improve health outcomes, and make products accessible to all.
Certified B Corporation, emphasizing responsible social and environmental practices, accountability, and transparency.
Product and market positioning
Offers clinically-proven, condition-specific probiotics developed with leading microbiome research partners.
Flagship products are practitioner-only, premium, and non-discounted, with a strong evidence base.
Holds #1 position in Australian pharmacy for both adult and kids probiotics.
Financial and operational performance FY26
International revenue reached $1.8m, up 26% from FY25, with gross margin at ~68%.
Operating expenses were $1.82m, with net loss narrowing to $649k, approaching breakeven.
Group gross profit was $1.21m, and international gross margin was 7pp above domestic.
Latest events from Biome Australia
- FY26 saw 30% revenue growth, record profit, and strategic moves for future margin expansion.BIO
H2 2026 - FY26 delivered record revenue, profit, and margin, with global expansion and new China entry ahead.BIOInvestor presentation
- Record FY26 revenue, strong cash flow, and top probiotic market position achieved.BIOQ4 2026 TU
- Record revenue and profit growth, margin expansion, and clinical strength drive global momentum.BIOStatus update
- Q3 FY26 saw record probiotic sales, strong cash position, and continued growth across all segments.BIOQ3 2026 TU
- Achieved first net profit and 41.6% revenue growth, with strong global expansion and innovation.BIOH2 2025
- Sales revenue up 80% to $13.01m, gross margin over 60%, and positive EBITDA in H2 FY24.BIOH2 2024
- Record revenue and profit growth, strong margins, and expanding international presence.BIOH1 2026
- First net profit, record sales, and expanded distribution highlight strong H1 FY25.BIOH1 2025